RU58841

RU58841 is a pure, non-steroidal androgen receptor (AR) antagonist originally developed by Roussel-Uclaf in the late 1980s for androgen-dependent skin conditions. Unlike finasteride or dutasteride — which work upstream by blocking 5α-reductase and lowering DHT synthesis — RU58841 works at the receptor itself, physically occupying the ligand-binding pocket so that DHT (and any other androgen) can't activate the follicle. That distinction is the entire reason this compound matters to anyone running AAS.

Competitive Androgen Receptor Blockade#

RU58841 binds the AR ligand-binding domain with affinity comparable to DHT itself, displacing endogenous androgens without triggering downstream transcription. It's a pure antagonist — no partial agonist activity, no SARM-like tissue selectivity at the receptor level. What gives it selectivity is the delivery route, not the pharmacology: topical application concentrates the drug in the scalp while systemic levels stay low because the parent compound is rapidly hydrolyzed to inactive metabolites by hepatic and plasma esterases.

"RU58841, given by topical application, was found to be a very potent antiandrogen exerting a strong activity at the cutaneous level, but only a weak systemic effect." — Battmann T. et al., Journal of Steroid Biochemistry and Molecular Biology, 1994

For the reader, this is the whole pitch: receptor-level blockade at the follicle without the systemic anti-androgen load that comes with oral bicalutamide or the neurosteroid disruption linked to oral 5-ARIs.

Why Receptor Blockade Beats 5-AR Inhibition On Cycle#

Finasteride and dutasteride only reduce conversion of testosterone → DHT. They do nothing against:

• Trenbolone and other 19-nor compounds that bind AR directly without 5α-reduction
• DHT-derivatives already in their active form — Anavar, Winstrol, Masteron, Anadrol, Proviron — which are essentially pre-reduced and walk straight past finasteride
• Nandrolone's AR-active metabolites

RU58841 doesn't care what's binding. Whether it's DHT from endogenous testosterone, trenbolone, or a stanozolol metabolite, the receptor is blocked. This is why physique-focused users running harsh cycles treat RU58841 as the cornerstone of a serious on-cycle hair-defense stack — it's the only mechanism that actually engages the androgens oral 5-ARIs can't touch.

Localized Action in the Dermal Papilla#

AGA is driven by androgen signaling inside the dermal papilla cells of genetically susceptible follicles, which triggers progressive miniaturization of the hair shaft with each cycle. Topical RU58841 delivered in an anhydrous ethanol/PG vehicle penetrates the stratum corneum and concentrates in the pilosebaceous unit, occupying follicular AR and interrupting the miniaturization cascade. In a human scalp xenograft model, this translated to measurable regrowth, not just stabilization:

"Topical application of RU58841 at 5% led to a significant increase in both the number and length of hairs produced by balding human scalp grafts." — De Brouwer B. et al., British Journal of Dermatology, 1997

Confirmation in the stumptailed macaque — the gold-standard primate model for AGA — showed dose-dependent improvement across multiple morphological endpoints:

"RU58841 produced a dose-dependent increase in hair density, shaft diameter and shaft length in this primate model of androgenetic alopecia." — Pan HJ. et al., Endocrine, 1998

Practically: expect stabilization first, then gradual recovery of shaft caliber in miniaturized-but-living follicles. Fully dormant follicles on advanced (NW4+) scalps respond inconsistently — RU is a preservation tool first and a regrowth tool second.

Pharmacokinetic Rationale for Daily Topical Dosing#

RU58841 has a short effective window at the follicle. The parent compound clears quickly from systemic circulation (hydrolyzed to inactive metabolites within hours), and local scalp concentrations follow a comparable decay. Receptor antagonism is occupancy-dependent — once the drug washes out, AR is available again, and any circulating androgen can resume signaling. That's why once-daily application is the minimum effective cadence, and why aggressive users on heavy cycles split 50–75 mg AM/PM to maintain continuous occupancy.

It's also why the vehicle matters so much. RU58841 hydrolyzes in aqueous solution, which degrades the active drug before it ever reaches the follicle:

"RU58841 is highly unstable in water-based vehicles; the consensus best practice is a 70% ethanol / 30% PG solution, mixed just before use and stored in the dark." — r/tressless Community, 2024

This is also the mechanistic reason to separate RU58841 application from water-based minoxidil by 30–60 minutes and to avoid same-day microneedling — the latter both degrades local drug and spikes systemic absorption, which is the single most common way users trigger anti-androgenic side effects on an otherwise well-tolerated compound.

Why It's Agnostic to the DHT Pathway#

The clearest way to frame RU58841 against the rest of the hair-loss toolkit:

The preclinical literature describes RU58841 as a pure, receptor-level blocker with a clean antagonist profile:

"RU58841, a pure nonsteroidal antiandrogen, acts as a competitive antagonist at androgen receptors and demonstrates efficacy in several preclinical models of androgen-dependent disorders." — Allan GF, Sui Z., Nuclear Receptor Signaling, 2003

For the physique-focused reader: this is the compound that lets you run tren, mast, var, or a heavy oral stack without watching your hairline recede — provided you use it daily, mix it correctly, and commit to the 4–6 month timeline before judging response.

Common (most users)#

• Scalp irritation, dryness, flaking — almost always the PG/EtOH vehicle, not the RU itself. Drop to 20% PG, alternate nights, or apply to fully dry scalp only. A ceramide moisturizer in the morning handles most cases.
• Initial shed (weeks 4–8) — a telogen shed on initiation is expected and actually a good sign (follicles cycling into anagen). Do not bail. Ride it out; real regrowth assessment is at 4–6 months.
• Sticky/greasy scalp feel — PG is hygroscopic. Apply at night, let it dry 20–30 minutes before hitting the pillow, wash hair in the morning if it bothers you.
• Interaction with water-based minoxidil — not a "side effect" per se, but co-application degrades the RU. Separate by 30–60 minutes or run one AM and the other PM.

Uncommon (dose-dependent or individual)#

• Mild systemic anti-androgenic symptoms — fatigue, flattened libido, softer erections, slight nipple sensitivity. Almost always tied to high doses (75+ mg/day), broken skin, or stacking application with same-day microneedling. Back off to 25–50 mg/day on intact scalp and symptoms resolve within 1–2 weeks.
• Irritant contact dermatitis — persistent redness, itch, burning beyond the first two weeks. Pause 1 week, restart at a lower strength (2.5%) or a lower-PG vehicle. Add a scalp barrier product on off-days.
• Acne along the hairline/forehead — PG plus occlusion plus an AR antagonist redistributing sebaceous activity. Ketoconazole 2% shampoo 2×/week and a salicylic acid cleanser usually resolve it.
• Unknowns on bloodwork — if you're already pulling labs on cycle, LH/FSH, total/free T, E2, SHBG, and prolactin cover the bases. RU58841 has no dedicated human PK/endocrine dataset, so pattern-match against your own baseline rather than published norms.

"RU58841, given by topical application, was found to be a very potent antiandrogen exerting a strong activity at the cutaneous level, but only a weak systemic effect." — Battmann et al., J Steroid Biochem Mol Biol (1994)

That "weak systemic effect" is the entire safety thesis. It holds at 50 mg/day on intact scalp. It starts to bend when you push dose, damage the skin, or microneedle the same day.

Rare but serious#

• Pronounced anti-androgenic syndrome — significant libido loss, erectile dysfunction, depressive flattening, gynecomastia-like changes. Stop immediately, get full hormone panel, expect recovery over weeks to months. Almost exclusively reported in users combining high topical doses with same-day microneedling or applying to compromised skin.
• Theoretical HPG-axis suppression — no formal human data exist. If on-cycle LH/FSH or post-PCT recovery looks worse than a comparable cycle without RU, that's your signal.
• Severe contact reaction / chemical burn — from poorly mixed vehicle or contaminated raw powder. Stop, switch vendors, HPLC-test the next batch.
• Unknown long-term effects — no 5- or 10-year human data. This is the honest ceiling on what anyone can tell you about RU58841. Most users accept it; you should go in knowing it.

Hard contraindications#

• Pregnancy or potential pregnancy — topical AR antagonists are teratogenic and can feminize a male fetus. Women who are pregnant, could become pregnant, or are breastfeeding must not use, handle the bottle, or share application surfaces with a partner who does. Non-negotiable.
• Known hormone-sensitive malignancy (prostate, male breast) — do not start without oncology sign-off.
• Broken, ulcerated, sunburned, or freshly microneedled scalp — absorption becomes unpredictable and systemic exposure can spike dramatically. Wait 24 hours minimum after microneedling before applying.
• Same-day stacking with microneedling — do not do it. Microneedle on one day, apply RU on the others.

Gender considerations and PCT#

• Men on AAS: RU58841 does not require PCT, does not meaningfully suppress the HPG axis at standard topical doses, and can run continuously through cycle, PCT, and cruise. It is one of the few hair tools that keeps working against trenbolone and DHT-derivative orals that finasteride can't touch.
• Men not on AAS: same protocol, no ancillaries required. When used as a finasteride replacement specifically to preserve systemic DHT signaling (libido, ejaculate, mood), the whole point is lost if you push dose high enough to get systemic blockade — the recommended dose is 50 mg/day on intact scalp.
• Women: the pregnancy contraindication is the gating issue. Topical AR antagonism is biologically plausible for female AGA but underexplored, and no responsible protocol exists around near-term conception.
• Semen quality / fertility: unlike oral 5-ARIs, RU58841 has no documented mechanism to reduce semen parameters at topical doses. If you're actively trying to conceive and want to avoid finasteride for that reason, RU58841 is the better-positioned tool — but keep application well away from the groin and wash hands after handling.